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Summary
Objective: Comparison of the effect of oral Contraceptives on hemo-
static variables in venous thrombosis patients (thrombosis while using
oral Contraceptives) with the effect in healthy control subjects. Our aim
was to assess whether some of these effects were more pronounced in
women who had suffered thrombosis, i.e., whether these were "hemo-
static hyperresponders". Study Design: A population-based case-con-
trol study, the Leiden Thrombophilia Study. Materials and Methods:
We investigated 99 pre-menopausal women, age 15-49 years, who had
used oral Contraceptives at the time of a first, objectively confirmed epi-
sode of deep-vein thrombosis. They were not pregnant, nor in puerperi-
um, nor had had a recent miscarriage, and were not using injectable pro-
gestogens, nor suffering from inherited coagulation defects. The me-
dian time between occurrence of deep-vein thrombosis and venepunc-
ture was 18 months, and 30 of the 99 women were still using oral con-
traceptives, while 69 had discontinued oral contraceptive use. In addi-
tion, a group of 153 control women (54 of them were oral contraceptive
users and 99 were non-users) were studied. The following hemostatic
variables were measured: APTT, factor VII, factor VIII, factor XII,
fibrinogen, prothrombin, total antithrombin, normalised activated pro-
tein C sensitivity ratio (n-APC-sr), protein C, protein S and free protein
S. Results: We found marked and significant effects of oral contracep-
tive use on the levels of several clotting factors, with an increase in fac-
tor VII, factor XII, protein C and a decrease in antithrombin, n-APC-sr
and protein S. Less marked effects that were non-significant or only
significant in either patients or controls, were an increase in factor VIII,
fibrinogen and prothrombin and a decrease in the APTT and free pro-
tein S. In the former thrombosis patients several of these effects of oral
Contraceptives were more pronounced than in healthy women: specifi-
cally on factor VII, antithrombin, n-APC-sr and protein C. Conclu-
sions: Our results of the effects of oral Contraceptives generally confirm
previous reports in healthy volunteers. Our data also show that in for-
mer deep-vein thrombosis patients these effects are more pronounced.
Apparently some women become "high hemostatic responders" when
exposed to oral Contraceptives, and they may be the women most vul-
nerable to its thrombogenic effects.
Correspondence to: Dr. F. R. Rosendaal, Department of Climcal Epidemiol-
ogy, Leiden University Hospital, Bldg 1-CO-P, P.O. Box 9600, 2300 RC




Since the report of Jordan in 1961 (1) on the association of oral con-
traceptive use and venous thromboembolism, it has become generally
accepted that there is an estrogen dose-dependent association between
oral contraceptive use and venous thrombosis (2-5). Recently several
studies have shown that the type of progestogen also plays a role in
the development of venous thrombosis during oral contraceptive use
(6-10). This resulted in renewed interest in the biological mechanisms
underlying venous thrombosis during oral contraceptive use.
The natural balance between the pro-coagulant, anti-coagulant and
fibrinolytic System may be disturbed by environmental factors, such äs
oral contraceptive use, orby hereditary defects in pro-coagulation, anti-
coagulation or fibrinolysis (l 1-12).
Previous studies have documented that oral Contraceptives may
stimulate pro-coagulation, inhibit anti-coagulation and stimulate fibri-
nolysis (13-16). Most studies on the hemostatic and fibrinolytic effects
of oral Contraceptives have been conducted in healthy volunteers. All
these studies showed changes in hemostatic variables, mostly within
physiological ranges and not all in the same, i.e. prothrombotic or anti-
thrombotic, direction (13-16). It is still unclear if and how these hemo-
static changes would result in an increased risk of venous thrombosis
(17-19). From the recent clinical studies (6-10) it appears that these
studies on intermediate end-points (plasma levels of hemostatic vari-
ables) have been of limited value in predicting clinical thrombosis risk.
Recently we described a gene-environment interaction between the
factor V Leiden mutation (20) and oral contraceptive use. The factor V
Leiden mutation, which leads to resistance to activated protein C (APC)
is commonly found among patients with venous thrombosis (21). In
women who are not using oral Contraceptives, this mutation increases
the risk of thrombosis 7-fold (22), while the combination of use of oral
Contraceptives and carriership of the factor V Leiden mutation in-
creases the risk 30- to 50-fold (9, 22). For the other less frequent
inherited clotting defects, i.e., protein C-, protein S- and antithrombin
deficiency, oral contraceptive use may also act synergistically on the
risk of development of venous thrombosis (23-27), though large data on
these rare inherited clotting defects are lacking.
To explain why some women using oral Contraceptives develop ve-
nous thrombosis and others not, interactions with other coagulation risk
factors may also play a role. We postulated that some women are more
prone to oral contraceptive-induced hemostatic changes and thus to
thrombotic disease.
The ideal design to study this question would be to randomise wom-
en with a previous thrombosis during oral contraceptive use, to either
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use of oral contraceptives or placebo This offers obvious practical
problems, and therefore we used a pseudo-randomized approach we
analysed hemostatic variables in the Leiden Thrombophiha Study
(LETS) (28) a population-based case-control study on nsk factors for
venous thrombosis In this study patients were invited for a visit at the
outpatient clinic at least six months after the thrombotic event At that
time, about one third of the women who had used oral contraceptives at
the time of the deep-vem thrombosis were still usmg oral contracep-
tives, two thirds had discontmued Smce the decision to contmue or dis-
contmue oral contraceptives will depend to a great extend on the opm-
ιοη of the physician, or on the feasibihty of other contraception meth-
ods, and not on the hemostatic balance, this may be considered a "ran-
dom" process, i e, pseudo-randomised In this way we assessed the ef-
fect of oral contraceptives in former thrombosis patients who developed
venous thrombosis dunng oral contraceptive use, and contrasted this
to the effect on hemostasis of oral contraceptives m healthy control
women
Materials and Methods ··
Patients and Control Subjects
The patients and methods of our study have been descnbed previously (22,
28) We invited 474 consecutive patients (272 women) with a first episode of
objectively demonstrated deep vem thrombosis (diagnosed by ultrasound, im
pedance plethysmography or phlebography) occurrmg between Jan l, 1988 and
Dec 31, 1992, aged less than 70 years and without a known mahgnant disorder
Patients had been selected from the files of three anticoagulation chmcs m the
Netherlands, which monitor anticoagulant treatment in all patients within a well
defined geographical area For each thrombosis patient we invited one age- and
sex-matched healthy control mdividual
Patients were seen after anticoagulant treatment had been discontmued for
at least 3 months [median time elapsed since the thrombotic event 18 months
(ränge 6 48)], unless treatment could not be discontmued
For the present analysis we selected from the original study (28), premeno
pausal women, aged 15-49 years, who were at the time of their thrombosis (or
similar date m the control women, the mdex date) not pregnant, nor in the puer
penum, did not have a recent miscarriage, and were not usmg progestogen
only methods Women receivmg anticoagulant treatment on the day of blood
collection were excluded (n = 6) Also women with a protein C- (n = 6, three of
them also used anticoagulant treatment), protein S- (n = 9), antithrombm (n = 2)
deficiency or the factor V Leiden mutation (n = 41) were excluded when ana-
lysmg the plasma levels of respectively protein C activity (29), total protein S
antigen and free protein S antigen (29), antithrombm activity (29) and normal-
ised activated protein C sensitivity ratio (n-APC-sr) (28) The cntena for diag-
nosis of these abnormahties have been descnbed before (29)
149 former thrombosis patients and 169 control women were mcluded m our
analysis (mean age 35 years) We divided this group in subgroups accordmg to
their oral contraceptive use m the month before the date of thrombosis and their
oral contraceptive use on day of blood collection 21 women of whom no data
were available on the use of oral contraceptives on the day of blood collection
were excluded This resulted m the followmg subgroups (see Figure 1) women
who developed deep-vem thrombosis dunng oral contraceptive use and were
still usmg oral contraceptives at blood collection (group A, n = 30), women who
developed deep-vem thrombosis dunng oral contraceptive use and did not use
oral contraceptives dunng blood collection (group B, n = 69), healthy control
women usmg oral contraceptives durmg blood collection (group C, n = 54) and
healthy control women not usmg oral contraceptives dunng blood collection
(group D, n = 99) Women who did not use oral contraceptives at the time of the
thrombosis are not mcluded in this analysis (n = 45)
Blood collection Blood was collected from the antecubital vem mto Sar
stedt Monovette® tubes, contammg 0 106 mmol/1 tnsodium citrate and centn-
fuged for 10 mm at 2000 g at room temperature The plasma was stored at
-70° C High-molecular-weight DNA was isolated from leucocytes and stored
at4°C
Laboratory measurements The followmg hemostatic variables were meas-
ured äs previous descnbed of the pro-coagulation System, activated partial
thromboplastm time (APTT) (29), factor VII activity (30), factor VIII activity
(31), factor XII activity (32), fibnnogen (30), prothrombm activity (29) and of
the anti-coagulation System, antithrombm activity (29), normahsed activated
protein C sensitivity ratio (n APC sr) (28), protein C activity (29), total protein
S antigen and free protein S antigen (29) Total protein S was measured by
polyclonal ELISA and free protein S was measured directly m plasma by
ELISA usmg two monoclonal antibodies specific for free protein S (Asserach-
rom free protein S, Stago Diagnostica, Asmeres-sur-Seme, France) Results of
the Activated Protein C resistance lest are expressed äs normahsed APC sensi
tivity ratlos (n-APC-sr) (33) Detection of the factor V Leiden mutation
(guanme-ademne replacement at nucleotide position 1691) was performed äs
descnbed previously (20)
Siafuficj We performed two mam compansons by Mann-Whitney-U-test
first between women usmg oral contraceptives and non-users This analysis
was performed among cases and controls Secondly, to identify women partic-
ularly sensitive to the effect of oral contraceptives, we mvestigated which ef
fects were most stnkmg m patients, äs compared with controls, i e a compan
son of the magnitude of the change m the former thrombosis patients, vs the
change m the control Smce our study was m pari hypothesis generating, we
report sigmficant äs well äs non significant results
Results
Given the complexity of the analysis a time frame is given m Fig l
This figure descnbes the events which divided the women m different
subgroups Of 149 deep-vem thrombosis patients, 104 had used oral
contraceptives at the time of the event, which was discontmued m 69,
i e, 30 stttl used it at the time of the venepuncture (data on 5 women
missmg) Of the 169 control women, 54 used oral contraceptives at the
time of the venepuncture, and 99 did not (16 rmssmg) This time frame
enabled us to venfy the effect of oral contraceptives m former thrombo-
sis patients whose thrombosis had happened dunng oral contraceptive
use [group A (n = 30) vs B (n = 69)] and m control subjects [group C
(n = 54) vs D (n = 99)]
We made several compansons (Table 1) Firstly, we checked the
effect of oral contraceptives on hemostatic variables m healthy women
by companng the values of the different hemostatic variables in the
control subjects who used oral contraceptives at the time of venepunc-
ture (n = 54) with the values in the subjects of the control group who
were non-users at the time of blood collection (n = 99), i e group C vs
group D Of the pro-coagulant variables all, except the APTT (lower),
were higher in the oral contraceptive-user group For the anti-coagulant
variables, free protein S was not really different when we compared







































Fig l Subgroups of women m the Leiden thrombophiha study Exclusion cn-
tena women who are above the age of 50, pregnant, postpartum, menopausal,
usmg mjectabte progestagens or anticoagulant treatment OC = oral contracep
tive, * unknown for 21 women
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Table l Mediän values (25th and 75th percentiles) of the hemostatic variables
in the different subgroups of the Leiden Thrombophilia Studyfi.e. araong for-
mer thrombosis patients (cases) who developed their thrombosis during oral
contraceptive (OC) use and healthy control subjects who continued or discon-
tinued using oral contraceptives
former thrombosis patients who












































































































6 to 48 monlhs after their thrombosisdate for the patients or indexdate for Controls.
significantly different (p<0.05) by Mann-Whitney-U-test.
Antithrombin, n = 29, 69. 54, 99 respectively
n-APC-sr, n = 22, 54, 53, 93 respectively.
Protein C, n= 30, 65, 54, 98 respectively
Protein S, n= 29, 68, 49, 98 respectively
Frec Protein S, n=29, 68, 46, 93 respectively.
oral contraceptive-user group and the other variables were lower in the
oral contraceptive-user group.
Secondly, we investigated the effect of oral contraceptive use in for-
mer thrombosis patients, who developed venous thrombosis during oral
contraceptive use, by comparing the values of the different hemostatic
variables in the former thrombosis patients who still used oral contra-
ceptives at the time of venepuncture (n = 30) with the values in the
group of former thrombosis patients who were non-users at the time of
blood collection (n = 69), i.e. group A vs. group B. Again, of the pro-
coagulant variables all, except the APTT (lower), were higher in the
oral contraceptive-user group. Of the anticoagulant variables all
median values, except for protein C (higher), were lower in the oral
contraceptive using group.
Thirdly, we compared effects of oral contraceptives between women
who had experienced a venous thrombosis during oral contraceptive
use and healthy women. For this comparison we compared the median
values of the hemostatic variables among former thrombosis patients
(cases) who developed their thrombosis during oral contraceptive use
and still used oral contraceptives (n = 30) vs. healthy control subjects
who also used oral contraceptives at the time of blood collection
(n = 54), i.e. group A vs. group C. The former thrombosis patients
group showed higher median levels of all pro-coagulant, except the
APTT (lower) and prothrombin (no difference), variables. The anti-
coagulant variables antithrombin, n-APC-sr and free protein S had





Fig. 2 Percentage of high responders in former thrombosis patients who
developed their thrombosis during oral contraceptive (OC) use and continued
using OCs (group A) and percentage of high responders in healthy control sub-
jects who were also using OCs at time of blood collection (group C).
* Significantly different (p <0.05) by Chi-Square lest.
Another way to compare these effects is shown in Fig. 2. This figure
shows the percentage of high responders in former thrombosis patients
who developed their thrombosis during oral contraceptive use (n = 30,
group A) and in healthy control subjects (n = 54, group C) who contin-
ued using oral contraceptives, i.e. women with values above the 75th
percentile or below the 25th percentile (depending how the variable
evolves when oral contraceptives are used). The percentiles were calcu-
lated on'the group women who consisted of 149 former thrombosis pa-
tients and 169 control subjects. The purpose of this table is to identify
possible high responders in this "pseudo randomized re-challenge
study". For almost all hemostatic variables there were more high re-
sponders in the group of former thrombosis patients.
Fourthly, we compared the changes in hemostatic variables induced
by oral contraceptives among former thrombosis patients (group A-B)
with the differences induced by oral contraceptives among healthy
women (group C-D), to see if women who developed venous thrombo-
sis during oral contraceptive use react differently when using oral con-
traceptives in comparison with healthy women who use oral contracep-
tives. The changes were greater in the former thrombosis patients group
for the procoagulant variables factor VII and for the anti-coagulant var-
iables antithrombin and protein C. For the pro-coagulant variables
APTT, factor VIII ,and for the anti-coagulant variable n-APC-sr the
changes were greater in the control women.
Fifthly, to make sure that the effect in the former thrombosis patients
group and still using oral contraceptives is really the effect of oral con-
traceptive use and not a post thrombotic state, we looked at baseline
values of control women who did not use oral contraceptives (n = 99)
and compared these values with the values of former thrombosis pa-
tients who discontinued using oral contraceptives (n = 69), i.e. group D
vs. group B. Most pro-coagulant variables were higher in the former
thrombosis patient group, except for the APTT and factor VII. For the
anti-coagulant variables, protein C, protein S and free protein S the me-
dian values were higher in the former thrombosis patients, the levels of
antithrombin were almost the same in both groups and n-APC-sr levels
were lower in the former thrombosis group.
Sixthly, we counted the total number of variables for which a wom-
an was a high responder, for example when she was a high responder
for n-APC-sr and for factor VIII her total number would be 2. The me-
dian (SD) were: for the group former thrombosis patients who devel-
oped their thrombosis during oral contraceptive use and who continued
using oral contraceptives (n = 30, group A); 5 (2.0), for the group for-
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mer thrombosis patients who developed their thrombosis during oral
contraceptive use and who discontinued using oral contraceptives
(n = 69, group C); 3 (1.6), for the group healthy women who used oral
contraceptives at the time of venepuncture (n = 54); 3 (1.7) and for the
group healthy control women who were not using oral contraceptives at
the time of venepuncture (n = 99); 2 (1.3). When comparing the groups,
the differences in group A vs. the group B, group C vs. group D, the
group A vs. group C and group B vs. group D were significant.
Oiscussion
In this pseudo-randomised study on the effect of challenging the he-
mostatic System by oral contraceptives in former thrombosis patients
(during oral contraceptive use), we found that the hemostatic System of
former thrombosis patients has a more pronounced reaction to oral con-
traceptives (especially for factor VII, antithrombin, n-APC-sr and pro-
tein C) in comparison to healthy control subjects.
The effects of oral contraceptive use among healthy control subjects
(Table 1) are generally in agreement with the findings of many random-
ised studies of different types of oral contraceptives (containing differ-
ent types and doses of estrogen and progestogen) and their effects on
hemostasis in healthy volunteers (13-16). Moreover this general trend
of oral contraceptive effect was the same among former thrombosis pa-
tients. Only for free protein S levels we did not observe reduced levels
associated with use of oral contraceptives äs has been described by
others (34-36).
The comparisons in our study also show that a woman who has ex-
perienced a deep-vein thrombosis, even if she is not currently using oral
contraceptives, still shows characteristics of changes in the hemostatic
System that are similar äs if sex steroids are involved (like in pregnant
women and in women using oral contraceptives) (15, 37), i.e. her
hemostatic system is in a more hyper coagulant or prothrombotic state.
A problem in our study is that we had no base-line values," so it is
possible that some differences were due to the post thrombotic state.
However, the time elapsed from the event to the time of blood collec-
tion was more than six months in all thrombosis patients. During these
six months the values of the hemostatic variables affected by the throm-
bosis event are likely to have returned to the values äs present before
the event.
When we compare the median values of the hemostatic variables
among former thrombosis patients (cases) and healthy control subjects
irrespective of their oral contraceptive Status, we see some of the estab-
lished risk factors for venous thrombosis, such äs high levels of factor VIII
(31), high levels of fibrinogen (30), low levels of antithrombin (29) and
low levels of n-APC-sr (28). Some effects are not related to thrombosis
risk, i.e., high levels of protein C (38), factor VII (30) and factor XII (32).
While for total protein S we found a significant decrease, we did not
find a decrease of free protein S with oral contraceptive use that one
usually expects. Several studies have shown decreases during oral con-
traceptive use, for both total and free protein S levels (34-3o, 39-42).
There is an important difference in design between the studies, how-
ever: most previously reported studies followed new-users for a rela-
tively short period of time, i.e. 6 to 12 months, while our study was a
cross-section of women, i.e., mainly long term users. A transient effect
would therefore had been apparent in the earlier studies, but less so in
our study. Several reports showed a marked effect during the first
months of oral contraceptive use and a decline of that effect with pro-
longed use (34,35,39,42).
In a next comparison it is remarkable that the difference in the effect
on hemostasis of oral contraceptives is more marked in women who
developed deep-vein thrombosis during oral contraceptive use than in
control subjects. There was a greater difference in former thrombosis
patients for the following hemostatic variables: pro-coagulation: factor
VII and anti-coagulation: antithrombin, protein C. Apparently the he-
mostatic system of a former thrombosis patient, still using oral contra-
ceptives, reacts different from a healthy control subject when using oral
contraceptives. Our data suggest that some women who will suffer a
thrombotic event show more pronounced effects of oral contraceptives.
This may point to some women being more vulnerable to the thrombo-
genic effects of oral contraceptives.
Considering the various analyses, most striking are the differences in
the median values of factor VII, antithrombin, n-APC-sr. Especially for
these hemostatic variables it seems likely that women who developed
deep-vein thrombosis during oral contraceptive use in the past, do re-
spond differently to oral contraceptive use than their control subjects.
As was recently described by others (43-47), we found an effect on
sensitivity to APC when women use oral contraceptives, also among
women who did not carry the factor V Leiden mutation. This acquired
APC-resistance is likely to be relevant in the pathogenesis of venous
thrombosis.
At this moment the types of progestogen used in oral contraceptives
are of special interest, since reports were published on the difference in
risk of venous thrombosis with the different types of progestogens used
in oral contraceptives (6-10). Although both second and third genera-
tion oral contraceptives were used by a substantial number of the wom-
en in our study, the numbers in subgroups became too small to make
meaningfut comparisons between types of oral contraceptives possible
(data not shown).
The differences in hemostatic variables in this study are between in-
dividuals, not within individuals, Information of the base line values is
lacking. On the other hand this study mimics the reality of the random-
ised trial sufficiently to infer that in some women the hemostatic system
reacts more pronounced to oral contraceptives than in other women.
The less likely alternative is that individuals who have had a previous
thromboembolic event only become "high hemostatic responders"
afterwards, when exposed to another risk factor for venous thromboem-
bolism, i.e. oral contraceptives.
In this pseudo-randomised study some women were still using oral
contraceptives after a thrombotic event (former thrombosis patients),
while others were barred from using oral contraceptives. Mostly it was
the physician who treated the patient, who had influenced this decision.
The only influence on this decision could be the extensiveness of the
deep venous thrombosis and possibly the combination with pulmonary
embolus.
The data derived from the different analysis in our study may help to
explain why women who use oral contraceptives, and have no other
known risk factors (such äs inherited clotting defects, malignancy), de-
velop thrombosis. Apparently some women· become "high hemostatic
responders" when exposed to oral contraceptives, and these may be the
women most vulnerable to its thrombogenic effects.
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